2023年1月12日,

2023年1月11日,雨果·珀里斯Catalio资本,随着知道的资本,导致825万美元的融资轮位于旧金山的螺旋疗法,临床分期启动开发治疗内耳疾病影响估计有4000万美国人。洪堡基金和其他家庭办公室投资者投资在两个现有投资者。螺旋,到目前为止,由创始人兼首席执行官乌戈·珀里斯,从投资者那里筹集了1850万美元,其中包括巴尔的摩卡姆登的合作伙伴。“听力损失和平衡失调是医学最大的未满足的需求。4.3亿全球听力受损,而没有fda批准的药物治疗,”查尔斯肢体博士说,螺旋的首席医疗官和首席教授的耳科Neurotology在旧金山加州大学。该公司将使用新的收益继续发展的领先候选人,spt - 2101治疗梅尼埃病(又名内耳眩晕病),可能导致发作性眩晕、耳鸣和听力损失。Catalio的新合作螺旋协议,前几天Catalio宣布与总部位于纽约的HealthCor合作管理,对冲基金已长达20年之久的医疗保健。两家公司计划制定公共股票对冲基金投资策略旨在利用全球生命科学投资机会。Catalio,由希腊神童乔治Petrocheilos r·雅各布博士和约翰霍普金斯大学的生物医学工程师Volgelstein,拥有36个举世闻名的科学家们的合作伙伴都开始几个成功的公司。多达30个诺贝尔奖得主“Catalio的一块,”据希腊倡议。 Catalio’s principals include Jonathan Blankfein, a former Goldman Sachs banker. The high-profile venture firm focused on life sciences has so far raised $566 million from three funds. Its most recent fund came last October, when it closed a new $85 million fund, Catalio Credit Opportunities Fund I. Last May, its Catalio Nexus Fund III closed on $381 million. Catalio has made 45 portfolio investments and exited five. Its recent investments include Perceive Biotherapeutics, Metagenomi, Ensoma, Medical Informatics, Haystack Oncology, Odyssey Therapeutics, Fractyl Health and Cartography Biosciences. Catalio has offices in New York, Baltimore and London. Spiral’s Phase 2 Trials SPT-2101, Spiral’s lead candidate, is a sustained-release steroid formulation. It is undergoing Phase 2 clinical trials in Australia. The randomized, placebo-controlled trial, which began this month, will investigate SPT-2101’s safety and efficacy as a single administration. Up to 30 subjects with Meniere’s disease are to be enrolled across four clinical centers in Australia. citybiz+ Sponsors “The safety profile and clinical data from the initial SPT-2101 trial shows great promise for the unmet needs of people suffering from Ménière’s disease,” said Dr. Jafri Kuthubutheen, principal investigator in SPT-2101’s Phase 2 trial. Kuthubutheen, who is a clinical associate professor in the Division of Surgery, Medical School at the University of Western Australia, called Ménière’s disease a “debilitating inner ear disorder usually diagnosed in patients between 40 to 60 years of age.” Spiral CEO Hugo Peris has a masters degree in health economics and pharmaco-economics from Spain’s Universitat Pompeu Fabra. Prior to starting Spiral, He spent seven years in Shanghai, working for Luqa Pharmaceuticals.